FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021007225> ?p ?o ?g. }

• W2021007225 endingPage "83" @default.
• W2021007225 startingPage "80" @default.
• W2021007225 abstract "No AccessJournal of UrologyAdult urology1 Jan 2007Prognostic Value of p53 for High Risk Superficial Bladder Cancer With Long-Term Followupis accompanied byHuman Bladder Carcinoma is Dominated by T-Regulatory Cells and Th1 Inhibitory Cytokines P.M.J. Moonen, B. van Balken-Ory, L.A.L.M. Kiemeney, J.A. Schalken, and J.A. Witjes P.M.J. MoonenP.M.J. Moonen Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author , B. van Balken-OryB. van Balken-Ory Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author , L.A.L.M. KiemeneyL.A.L.M. Kiemeney Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author , J.A. SchalkenJ.A. Schalken Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author , and J.A. WitjesJ.A. Witjes Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.08.110AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The risk of muscle invasive disease in a high risk patient with superficial bladder cancer is up to 50%. Identifying patients at risk for progression remains an unsolved problem. A suggested prognosticator is mutations in the p53 tumor suppressor gene. We determined the value of p53 mutation, as demonstrated by mutation analysis, in a clinically selected group of high risk patients with superficial bladder cancer. Materials and Methods: p53 Mutation analysis was performed by automated sequencing of bladder wash samples of 105 patients with high risk superficial bladder cancer. The mutation and WT groups were subsequently compared with regard to mortality, progression, disease worsening and the recurrence-free period. Results: A total of 29 patients had a mutation and 76 had WT. Median followup was 58.3 months (range 3 to 161). A total of 13 patients died of bladder cancer, including 6 of 29 with a mutation and 7 of 76 patients in the WT group. p53 Mutation had no significant prognostic value for decreased survival, progression or disease worsening. Recurrence-free survival was significantly lower in the WT group. Conclusions: We observed a trend toward a worse clinical outcome in high risk patients with a p53 mutation in the bladder wash. However, no significant differences were seen in clinical outcome parameters. Based on these data we conclude that the prognostic value of a p53 mutation is insufficient for individual policy making. References 1 : Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol1993; 150: 60. Link, Google Scholar 2 : Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol1986; 135: 920. Link, Google Scholar 3 : Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar 4 : Survival of patients with carcinoma in situ of the urinary bladder. Cancer1999; 85: 2469. Google Scholar 5 : Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol2004; 45: 292. Google Scholar 6 : p53, the cellular gatekeeper for growth and division. Cell1997; 88: 323. Google Scholar 7 : p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol1993; 143: 1389. Google Scholar 8 : p53 mutations in human cancers. Science1991; 253: 49. Google Scholar 9 : AJCC Cancer Staging Handbook TNM Classification of Malignant Tumors. In: Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Heidelberg: Springer-Verlag2002: 335. part IX. Google Scholar 10 Histological Typing of Urinary Bladder Tumours. International Histological Classification of Tumours, No. 10. Geneva, Switzerland: World Health Organization1973. Google Scholar 11 : Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol1994; 152: 388. Link, Google Scholar 12 : P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol1994; 12: 79. Google Scholar 13 : P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol2005; 6: 678. Google Scholar 14 : The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol2003; 169: 1219. Link, Google Scholar 15 : p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol2000; 38: 691. Google Scholar 16 : Can p53 staining be used to identify patients with aggressive superficial bladder cancer?. J Pathol2003; 200: 74. Google Scholar 17 : Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol2000; 16: 469. Google Scholar 18 : Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol1999; 162: 1496. Link, Google Scholar 19 : Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst1993; 85: 53. Google Scholar 20 : p53 mutations and prognosis in bladder tumors. J Urol1995; 153: 1097. Link, Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited bySerretta V, Ruggirello A, Dispensa N, Allegro R, Aragona F and Melloni D (2018) Multiplicity and History Have a Detrimental Effect on Survival of Patients With T1G3 Bladder Tumors Selected for Conservative TreatmentJournal of Urology, VOL. 180, NO. 3, (886-891), Online publication date: 1-Sep-2008.Related articlesJournal of Urology9 Nov 2018Human Bladder Carcinoma is Dominated by T-Regulatory Cells and Th1 Inhibitory Cytokines Volume 177Issue 1January 2007Page: 80-83 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsbladderbladder neoplasmsgenes, p53prognosisAcknowledgmentsDr. Seth P. Lerner reviewed the manuscript.MetricsAuthor Information P.M.J. Moonen Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author B. van Balken-Ory Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author L.A.L.M. Kiemeney Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author J.A. Schalken Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author J.A. Witjes Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2021007225 created "2016-06-24" @default.
• W2021007225 creator A5030962499 @default.
• W2021007225 creator A5045763456 @default.
• W2021007225 creator A5057728602 @default.
• W2021007225 creator A5060302039 @default.
• W2021007225 creator A5073418764 @default.
• W2021007225 date "2007-01-01" @default.
• W2021007225 modified "2023-10-17" @default.
• W2021007225 title "Prognostic Value of p53 for High Risk Superficial Bladder Cancer With Long-Term Followup" @default.
• W2021007225 cites W1991494214 @default.
• W2021007225 cites W1997216192 @default.
• W2021007225 cites W2000774400 @default.
• W2021007225 cites W2042316019 @default.
• W2021007225 cites W2051743890 @default.
• W2021007225 cites W2052040125 @default.
• W2021007225 cites W2075355958 @default.
• W2021007225 cites W2081194991 @default.
• W2021007225 cites W2109609879 @default.
• W2021007225 cites W2140178932 @default.
• W2021007225 cites W2140321800 @default.
• W2021007225 cites W2152858404 @default.
• W2021007225 cites W2170518050 @default.
• W2021007225 cites W2403272479 @default.
• W2021007225 cites W2410257367 @default.
• W2021007225 cites W317249572 @default.
• W2021007225 doi "https://doi.org/10.1016/j.juro.2006.08.110" @default.
• W2021007225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17162008" @default.
• W2021007225 hasPublicationYear "2007" @default.
• W2021007225 type Work @default.
• W2021007225 sameAs 2021007225 @default.
• W2021007225 citedByCount "33" @default.
• W2021007225 countsByYear W20210072252012 @default.
• W2021007225 countsByYear W20210072252013 @default.
• W2021007225 countsByYear W20210072252014 @default.
• W2021007225 countsByYear W20210072252015 @default.
• W2021007225 countsByYear W20210072252017 @default.
• W2021007225 countsByYear W20210072252018 @default.
• W2021007225 countsByYear W20210072252021 @default.
• W2021007225 countsByYear W20210072252022 @default.
• W2021007225 crossrefType "journal-article" @default.
• W2021007225 hasAuthorship W2021007225A5030962499 @default.
• W2021007225 hasAuthorship W2021007225A5045763456 @default.
• W2021007225 hasAuthorship W2021007225A5057728602 @default.
• W2021007225 hasAuthorship W2021007225A5060302039 @default.
• W2021007225 hasAuthorship W2021007225A5073418764 @default.
• W2021007225 hasConcept C105795698 @default.
• W2021007225 hasConcept C121332964 @default.
• W2021007225 hasConcept C126894567 @default.
• W2021007225 hasConcept C141071460 @default.
• W2021007225 hasConcept C143998085 @default.
• W2021007225 hasConcept C2776291640 @default.
• W2021007225 hasConcept C33923547 @default.
• W2021007225 hasConcept C61797465 @default.
• W2021007225 hasConcept C62520636 @default.
• W2021007225 hasConcept C71924100 @default.
• W2021007225 hasConceptScore W2021007225C105795698 @default.
• W2021007225 hasConceptScore W2021007225C121332964 @default.
• W2021007225 hasConceptScore W2021007225C126894567 @default.
• W2021007225 hasConceptScore W2021007225C141071460 @default.
• W2021007225 hasConceptScore W2021007225C143998085 @default.
• W2021007225 hasConceptScore W2021007225C2776291640 @default.
• W2021007225 hasConceptScore W2021007225C33923547 @default.
• W2021007225 hasConceptScore W2021007225C61797465 @default.
• W2021007225 hasConceptScore W2021007225C62520636 @default.
• W2021007225 hasConceptScore W2021007225C71924100 @default.
• W2021007225 hasIssue "1" @default.
• W2021007225 hasLocation W20210072251 @default.
• W2021007225 hasLocation W20210072252 @default.
• W2021007225 hasOpenAccess W2021007225 @default.
• W2021007225 hasPrimaryLocation W20210072251 @default.
• W2021007225 hasRelatedWork W1973996291 @default.
• W2021007225 hasRelatedWork W2319969327 @default.
• W2021007225 hasRelatedWork W2330575325 @default.
• W2021007225 hasRelatedWork W2365267743 @default.
• W2021007225 hasRelatedWork W2370579019 @default.
• W2021007225 hasRelatedWork W3081419012 @default.
• W2021007225 hasRelatedWork W3096145648 @default.
• W2021007225 hasRelatedWork W3197510923 @default.
• W2021007225 hasRelatedWork W42295635 @default.
• W2021007225 hasRelatedWork W2163803519 @default.
• W2021007225 hasVolume "177" @default.
• W2021007225 isParatext "false" @default.
• W2021007225 isRetracted "false" @default.
• W2021007225 magId "2021007225" @default.
• W2021007225 workType "article" @default.